Additionally, KAT8’s role in CRC suppression, the tumor resistance mechanisms associated with NBS1 K388 blockade, and the enhanced tumor-suppressive effects observed with the combination of Sirt2 inhibitors and Elesclomol have also been highlighted. The gene discussed is SIRT2; the disease is neoplasm.